Skip to main content
Download PDF

Correction: EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment

BMC Cancer volume 22, Article number: 1224 (2022) Cite this article

The Original Article was published on 14 September 2022

Correction: BMC Cancer 22, 982 (2022)

https://doi.org/10.1186/s12885-022-10070-z

Following publication of the original article [1], the authors identified an error in Fig. 1B. Patients with EZH2 mutation (n=7) have worse prognosis than patients without mutation (n=23). The updated Fig. 1 is supplied in this correction article.

Fig. 1
figure 1

Kaplan-Meier curves in patients with grade 1, 2, and 3a. A PFS and OS in patients treated with R-CHOP (EZH2 mutated vs. unmutated); B PFS and OS in patients treated with R-Bendamustine (EZH2 mutated vs. unmutated). C PFS and OS in EZH2 mutated patients (R-CHOP vs. R-Bendamustine). PFS Progression-free survival. OS: Overall survival

Full size image

The original article [1] has been corrected.

Reference

  1. Martínez-Laperche C, Sanz-Villanueva L, Díaz Crespo FJ, et al. EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment. BMC Cancer. 2022;22:982. https://doi.org/10.1186/s12885-022-10070-z.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gregorio Maranon Health Research Institute (IiSGM), Madrid, Spain

    C. Martínez-Laperche, L. Sanz-Villanueva, F. J. Díaz Crespo, P. Muñiz, D. Carbonell, M. Chicano, J. Suárez-González, J. Menárguez, M. Kwon, J. L. Diez Martín, I. Buño & M. Bastos Oreiro

  2. Department of Hematology, Gregorio Marañón General University Hospital, Gregorio Marañón Health Research Institute (IiSGM), C/ Doctor Esuerdo 46, 28007, Madrid, Spain

    C. Martínez-Laperche, L. Sanz-Villanueva, P. Muñiz, R. Martín Rojas, D. Carbonell, M. Chicano, M. Kwon, J. L. Diez Martín, I. Buño & M. Bastos Oreiro

  3. Pathology Department, Gregorio Maranon General University Hospital, Madrid, Spain

    F. J. Díaz Crespo & J. Menárguez

  4. Genomics Unit, Gregorio Maranon General University Hospital, IiSGM, Madrid, Spain

    J. Suárez-González & I. Buño

  5. Department of Medicine, School of Medicine, Complutense University of Madrid, Madrid, Spain

    J. L. Diez Martín

  6. Department of Cellular Biology, School of Medicine, Complutense University of Madrid, Madrid, Spain

    I. Buño

Authors
  1. C. Martínez-Laperche
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Sanz-Villanueva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. J. Díaz Crespo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Muñiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Martín Rojas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Carbonell
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Chicano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Suárez-González
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. Menárguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J. L. Diez Martín
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. I. Buño
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M. Bastos Oreiro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Bastos Oreiro.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Martínez-Laperche, C., Sanz-Villanueva, L., Díaz Crespo, F.J. et al. Correction: EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment. BMC Cancer 22, 1224 (2022). https://doi.org/10.1186/s12885-022-10335-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12885-022-10335-7

BMC Cancer

ISSN: 1471-2407

Contact us